Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia (CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective imatinib-mesylate...

U937 cells display the strongest response to D3 treatment compared to the other cell lines, with over 50% CD14 expression occurring by 72 h in the D3 and RA + D3 treated cases (Fig. 3A,B).

To validate CLL-1 as a target antigen for CAR-T cell therapy against AML, we first evaluated CLL-1 expression in AML cell lines and primary AML blasts. The chronic myeloid leukemia cell line K562 does not express CLL-1 (Figure S1A) and we used it as a negative control.

Fixed gene-modified K562 cells can serve as effective aAPC to expand CMV-specific CTL for therapeutic use in patients after stem cell transplantation. Our findings have implications for broader understanding of the immune evasion mechanisms used by leukemia and other tumors. Keywords: Artificial APC, Cytomegalovirus, Cytotoxic T cell, Fixation.

Download scientific diagram | Effect of PMA on the expression of CD11b and CD14 on the surface molecule of K562 cells. (A) CD11b expression group prior to and following induction (B) CD14...

Jul 28, 2023 · Reduced levels of CD56+ NK cells and CD14+ monocytes (Fig. 3d, f) are therefore the most likely reason for the reduced direct cytotoxicity against K562 (Fig. 2a) and trastuzumab-mediated ADCC ...

Feb 20, 2007 · K562 cells expressing α4 (K562-α4) attached to both VCAM-1-Fc and CD14-Fc in an α4β1-dependent manner, in the presence of 1 mM Mn 2+, as demonstrated by addition of anti-functional mAbs directed against the α4 subunit (Fig. 2 B).

Jul 6, 2010 · K562 supernatant affected CD14 and CD1a expressions already in the first 24 h of culture (Fig. 3b, d). In the presence of K562 supernatant, more cells remained expressing CD14 without CD1a expression at all times studied.

The morphological changes of K562 cells were observed by light microscope and electron microscope; the differentiation phenotypes of K562 cells were identified by the cytochemical staining of POX, PAS, alpha-NAE and immunocytochemistry of CD13, CD14, CD68, and the effect of Wnt5a on cell cycle distribution of K562 cells was detected by flow ...

Jul 1, 2016 · At a low dose, polyphyllin D increased CD14 expression on the surface of K562 cells and induced cells to differentiate into monocytes or mature macrophages. These data suggest that polyphyllin D has the potential to be a potent therapeutic agent for treating human chronic myelogenous leukemia.